A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease

June 3, 2026 updated by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

A Multicenter, Randomized, Open-label, Active-controlled Phase II Clinical Trial to Explore the Efficacy and Safety of Different Doses of TQC3927 Inhaled Powder in Patients With Chronic Obstructive Pulmonary Disease

This is a multicenter, randomized, open-label, positive-drug controlled study designed to evaluate the preliminary efficacy and safety of different doses of TQC3927 inhaled powder for short-term treatment of patients with chronic obstructive pulmonary disease, and to observe the symptoms and pharmacokinetic (PK) characteristics of participants.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

90

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Jintong Li, Doctor
  • Phone Number: 15300059186
  • Email: gcpljt@189.cn

Study Contact Backup

Study Locations

  • China
    • Guangxi
      • Yulin, Guangxi, China, 537000
        • The First People' Hospital Of YuLin
        • Contact:
    • Heilongjiang
      • Daqing, Heilongjiang, China, 163000
        • Da Qing Long Nan Hospital
        • Contact:
    • Henan
      • Anyang, Henan, China, 455099
        • The People's Hospital of Anyang City
        • Contact:
        • Contact:
    • Hubei
      • Yichang, Hubei, China, 443003
        • Yichang Central People's Hospital
        • Contact:
    • Hunan
      • Xiangtan, Hunan, China, 411200
        • Xiangtan County People's Hospital
        • Contact:
    • Jiangsu
      • Yangzhou, Jiangsu, China, 225000
        • Northern Jiangsu People's Hospital
        • Contact:
      • Yixing, Jiangsu, China, 214200
        • Yixing People'S Hospital
        • Contact:
    • Jiangxi
      • Nanchang, Jiangxi, China, 330000
        • Jiangxi Provincal People's Hospital
        • Contact:
    • Jilin
      • Siping, Jilin, China, 136099
        • Siping Central People's Hospital
        • Contact:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200433
        • Shanghai Pulmonary Hospital
        • Contact:
    • Shanxi
      • Linfen, Shanxi, China, 041099
        • Linfen Central Hospital
        • Contact:
    • Sichuan
      • Chengdu, Sichuan, China, 610031
        • Chengdu Third People's Hospital
        • Contact:
          • Guoping Li, Doctor
          • Phone Number: 18982791605
          • Email: lzlgp@163.com
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300140
        • The Fourth Central Hospital of Tianjin
        • Contact:
    • Xinjiang
      • Ürümqi, Xinjiang, China, 832008
        • The First Affiliated Hospital of Shihezi University Shihezi
        • Contact:
    • Zhejiang
      • Wenzhou, Zhejiang, China, 325027
        • The 2th School of Medicine ,WMU/The 2th affiliated Hospital and Yuying Children's Hospital of WMU
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Sign an informed consent form before the trial to fully understand the purpose, procedure, and possible adverse reactions;
  • Age: 40 years ≤ age ≤ 75 years (calculated from the date of signing the informed consent form), gender not limited;
  • Participants' body mass index (BMI) is within the range of 18~30 kg/m2 (including the borderline), and their weight is ≥45kg;
  • Diagnosed with Chronic Obstructive Lung Disease (COPD) according to the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria, and symptoms consistent with COPD for at least 1 year before the screening visit (V1);
  • Participants must have discontinued short-acting β2-adrenergic receptor agonist (SABA) for at least 6 hours and short-acting cholinergic receptor antagonist (SAMA) for at least 8 hours before starting any pulmonary function tests;
  • Participants must be current or former smokers with a smoking history of ≥10 pack-years (pack-year: number of packs per day × number of years of smoking, such as 1 pack of 20 cigarettes per day for 10 consecutive years, or 10 cigarettes per day for 20 consecutive years); former smokers are defined as those who have quit smoking for at least 6 months prior to Visit 1. Note: Use of pipes, cigars, and e-cigarettes cannot be used to calculate packs/year;
  • Trained participants are able to perform acceptable and reproducible pulmonary function tests according to American Thoracic Society/European Respiratory Society (ATS/ERS) 2005 criteria;
  • Participants voluntarily sign informed consent forms and have no plans for pregnancy within 90 days from the start of treatment to the last dose, and voluntarily use medically approved contraception (including with their partners);
  • Trained participants are able to correctly use a pressure metered-dose inhaler (pMDI), dry powder inhaler (DPI) inhaler for drug administration;
  • Participants are able to attend study visits on time and complete the visit content;

Exclusion Criteria:

  • Participants currently diagnosed with asthma (including asthma with COPD) or with a history of asthma, based on the investigator's judgment;
  • Participants with a current life-threatening COPD history;
  • Participants with concurrent active or clinically significant respiratory illnesses that significantly impact the study;
  • Participants with serious illnesses other than COPD, or abnormalities in laboratory tests, electrocardiograms, medical history, or physical examinations;
  • Participants who have undergone lung volume reduction surgery, lobectomy/segmentectomy, or are expected to undergo lung surgery during the study period within 12 months prior to V1;
  • Participants who have developed pneumonia or lower respiratory tract infections requiring antibiotic treatment within 8 weeks prior to V1 or between V1 and V3;
  • Participants with clinically significant abnormalities on chest computed tomography (CT);
  • Participants currently using positive pressure ventilation;
  • Participants requiring long-term oxygen therapy (oxygen therapy time > 15 minutes). 10. Individuals undergoing pulmonary rehabilitation;
  • Participants who changed their smoking status (i.e., started or stopped smoking) or began a smoking cessation program within 6 weeks prior to screening;
  • Individuals with unstable or life-threatening heart disease;
  • Individuals using non-selective oral beta-blockers;
  • Individuals with unstable or uncontrolled hypertension;
  • Abnormal values in clinically significant safety laboratory tests determined by the investigator at the screening visit;
  • Positive results for human immunodeficiency virus (HIV); positive results for hepatitis B surface antigen (HBsAg); positive results for hepatitis C virus (HCV) antibody and supporting documentation.
  • Individuals with a confirmed history of neurological or psychiatric disorders, including epilepsy or dementia requiring treatment;
  • Individuals with a history or current condition of neuropsychiatric, respiratory, cardiovascular, digestive, hematopoietic, lymphatic, immune, hepatic or renal insufficiency, endocrine, musculoskeletal, or other diseases;
  • Individuals who have participated in any drug or medical device clinical trial and received a study intervention within 4 weeks or 5 drug half-lives (whichever is longer) prior to screening;
  • Individuals who have lost or donated more than 400 ml of blood within 3 months prior to the trial. 21. Individuals with a known history of drug or food allergies, especially to components similar to the investigational drug;
  • Individuals who have frequently consumed alcohol within the 6 months prior to screening, or who have tested positive for alcohol in a breathalyzer test;
  • Individuals who have received a live attenuated vaccine within 28 days prior to randomization, an inactivated vaccine within 7 days prior to randomization, or are scheduled to receive a vaccine during the study period;
  • Individuals with a history of any organ or systemic malignancy within the past 5 years;
  • Individuals with a history of drug abuse within the past 2 years, or who have tested positive for drug abuse;
  • Individuals assessed by the investigators as unable to discontinue prohibited drugs as specified in the protocol during the screening and treatment phases of this study;
  • Pregnant or lactating women, or female participants with positive pregnancy test results;
  • Individuals with difficulty obtaining venous blood or a history of fainting from needles or blood loss;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 400 μg TQC3927 inhalation aerosol
The experimental group was given 400 μg of TQC3927 inhalation powder twice daily for a total of 14 days.
Drug: TQC3927 inhalation aerosol
TQC3927 inhaled powder: TQC3927 exhibits dual-target activity against anticholinergic antagonists and adrenergic receptor agonists (MABA).
Experimental: 600 μg TQC3927 inhalation aerosol
The experimental group was given 600 μg of TQC3927 inhalation powder twice daily for a total of 14 days.
Drug: TQC3927 inhalation aerosol
TQC3927 inhaled powder: TQC3927 exhibits dual-target activity against anticholinergic antagonists and adrenergic receptor agonists (MABA).
Active Comparator: glycopyrronium bromide and formoterol inhaled aerosol
The positive control group for glycopyrronium bromide formoterol inhalation aerosol (Baiwoping® Lingchang®) was given twice daily for 14 days.
Drug: Glyceryl bromide/formoterol inhalation aerosol
Glycerone bromide formoterol inhaler: long-acting adrenergic receptor agonists (LABA) + long-acting anticholinergic antagonists (LAMA) combination therapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The area under the FEV1 curve (AUC)
Time Frame: Within 14 days
The area under the curve (AUC) of the change in FEV1 from baseline (ΔFEV1) 0-12 h after the first dose of Day 14.
Within 14 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
FEV1 peak
Time Frame: Within 14 days
Changes in peak FEV1 from baseline after first administration on day 1, day 8, and day 14.
Within 14 days
FEV1 morning valley value
Time Frame: Within 14 days
Changes from baseline in FEV1 morning trough values at Day 2, D8 before the first dose, and 12 hours after the second dose on Day 14 (Day 15).
Within 14 days
The area under the FVC curve (AUC)
Time Frame: Within 14 days
The areas under the curve (AUC) of FEV1 and FVC changes from baseline (ΔFEV1 and ΔFVC) at 0-6 hour, 0-8 hour, and 0-12 hour after the first dose of D1; the areas under the curve (AUC) of FEV1 changes from baseline (ΔFEV1) and FVC changes from baseline (ΔFVC) at 0-6 hour, 0-8 hour, and 0-12 hour after the first dose of Day 14.
Within 14 days
FEV1
Time Frame: Within 14 days
The change in FEV1 from baseline at each time point within 12 hours after the first dose on Day 1 and the first dose on Day 14.
Within 14 days
CAT rating
Time Frame: Within 14 days
Changes from baseline in Patient Self-Assessment Test (CAT) scores for D8 and D14 chronic obstructive pulmonary disease.
Within 14 days
Scale for measuring dyspnea, cough, and sputum
Time Frame: Within 14 days
Changes in the total score and individual item scores of the Dyspnea, Cough and Sputum Scale (BCSS) from baseline at each time point from Day 1 to Day 7, Day 8 to Day 14, and Day 1 to Day 14.
Within 14 days
Salbutamol Sulfate Inhalation Aerosol
Time Frame: Within 14 days
Frequency and number of uses of the emergency medication salbutamol sulfate inhaler (Ventolin®) during a 2-week treatment period.
Within 14 days
Ctroμgh
Time Frame: Within 14 days
Ctroμgh: Blood drug concentration at the end of the dosing interval (before the next dose); PK: The entire process of absorption, distribution, metabolism, and excretion in the body, and the pattern of blood drug concentration changes over time.
Within 14 days
Maximum mid-expiratory flow
Time Frame: Within 14 days
Changes in maximum mid-expiratory flow (MMEF) from baseline at each time point after the first dose on day 1, day 8, and day 14.
Within 14 days
Adverse events (AEs)
Time Frame: Within 7 weeks
Adverse events (AEs) refer to all adverse medical events that occur after a participant receives the investigational drug. These can manifest as symptoms, signs, illnesses, or abnormal laboratory tests, but are not necessarily causally related to the investigational drug.
Within 7 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

January 1, 2027

Study Registration Dates

First Submitted

June 3, 2026

First Submitted That Met QC Criteria

June 3, 2026

First Posted (Actual)

June 8, 2026

Study Record Updates

Last Update Posted (Actual)

June 8, 2026

Last Update Submitted That Met QC Criteria

June 3, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TQC3927-II-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Obstructive Pulmonary Disease

Clinical Trials on TQC3927 inhalation aerosol

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe